Literature DB >> 12704668

Two novel in vitro human hepatoblastoma models, HepU1 and HepU2, are highly characteristic of fetal-embryonal differentiation in hepatoblastoma.

Stefanie Scheil1, Silvia Hagen, Silke Brüderlein, Ivo Leuschner, Wolfgang Behnisch, Peter Möller.   

Abstract

Using comparative genomic hybridization (CGH), we present a genome-wide screening of a mixed mesenchymal-epithelial hepatoblastoma, its recurrence and 2 novel hepatoblastoma cell lines raised from the ascites, 18 (HepU1) and 23 (HepU2) months after diagnosis of a hepatoblastoma in a 35-month-old boy. Both cell lines were also characterized by GTG-banding, multicolor-fluorescence in situ hybridization (M-FISH) and multicolor banding (M-Band). On the basis of CGH, we compared the cytogenetics of histologically different tumor areas of the parental tumor and its recurrence with the hepatoblastoma cell lines. We found different CGH profiles in the parental tumor rev ish enh(1q31-q32,8p,12,17,20,X), dim(4q34-q35,18q23)[cp] and its recurrence rev ish enh(8q24,17,Xq26-q28), dim(7q11.2-q21,13q34)[cp]. Although both epithelial cell lines were obtained at different times and the clonal ancestor of HepU2 had been exposed to a higher cumulative dose of chemotherapy, HepU1 and HepU2 have an identical karyotype: 48-56,XY,+Y,dup(2)(q32-q34),t(3;4)(q21;q34),+8,+12,+13, +17,+t(18;19)(q21;q?),+20[cp] and identical CGH profiles: rev ish enh(2q24-q33,8,12,13q,17,20), dim(4q34-q35,18q22-q23). In common with previously described hepatoblastoma cell lines, HepU1 and HepU2 demonstrate a gain of chromosome 20. The in situ aberrations most closely resembling that of HepU1 and HepU2 were found in areas of fetal-embryonal differentiation of the primary tumor. Interestingly, both cell lines mimic this histology in their three-dimensional growth pattern in vitro. HepU1 and HepU2 are thus cytogenetically and phenotypically highly characteristic of fetal-embryonal hepatoblastoma. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2003        PMID: 12704668     DOI: 10.1002/ijc.11082

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  4 in total

1.  Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer.

Authors:  Beatrice Bissig-Choisat; Claudia Kettlun-Leyton; Xavier D Legras; Barry Zorman; Mercedes Barzi; Leon L Chen; Mansi D Amin; Yung-Hsin Huang; Robia G Pautler; Oliver A Hampton; Masand M Prakash; Diane Yang; Malgorzata Borowiak; Donna Muzny; Harsha Vardhan Doddapaneni; Jianhong Hu; Yan Shi; M Waleed Gaber; M John Hicks; Patrick A Thompson; Yiling Lu; Gordon B Mills; Milton Finegold; John A Goss; D Williams Parsons; Sanjeev A Vasudevan; Pavel Sumazin; Dolores López-Terrada; Karl-Dimiter Bissig
Journal:  J Hepatol       Date:  2016-04-23       Impact factor: 25.083

2.  Characterisation of the cell line HC-AFW1 derived from a pediatric hepatocellular carcinoma.

Authors:  Sorin Armeanu-Ebinger; Julia Wenz; Guido Seitz; Ivo Leuschner; Rupert Handgretinger; Ulrike A Mau-Holzmann; Michael Bonin; Bence Sipos; Jörg Fuchs; Steven W Warmann
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

3.  Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma.

Authors:  Stefania Crippa; Pierre-Benoit Ancey; Jessica Vazquez; Paolo Angelino; Anne-Laure Rougemont; Catherine Guettier; Vincent Zoete; Mauro Delorenzi; Olivier Michielin; Etienne Meylan
Journal:  EMBO Mol Med       Date:  2017-11       Impact factor: 12.137

Review 4.  Hepatoblastoma: A Need for Cell Lines and Tissue Banks to Develop Targeted Drug Therapies.

Authors:  Rishi Raj Rikhi; Kimberlee K Spady; Ruth I Hoffman; Michael S Bateman; Max Bateman; Lisa Easom Howard
Journal:  Front Pediatr       Date:  2016-03-21       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.